| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1996;94:2337-2340.)
© 1996 American Heart Association, Inc.
Articles |
Fish Consumption, Fish Oil, Lipids, and Coronary Heart Disease
From the Nutrition Committee of the American Heart Association
Key Words: AHA Medical/Scientific Statements • lipids • diet • coronary disease • fatty acids
 |
Introduction |
|---|
 Top Introduction What Are Omega-3 Fatty...Fish Intake and Risk...Fish Intake and CHDConclusionsReferences |
|---|
Reducing intake of saturated fat and dietary cholesterol and avoiding excess calories, which can lead to obesity, remain the cornerstore of the dietary approach to decreasing risk of atherosclerotic vascular disease. During the past 20 years, however, there has been renewed interest in other dietary components that might favorably improve lipid profiles and reduce risk of coronary heart disease (CHD). Fish and fish oil, rich sources of omega-3 fatty acids, have sparked intense interest in both epidemiological studies, which suggest a favorable effect on CHD, and metabolic ward studies, which show a striking improvement in lipid profiles in hyperlipidemic patients. Confusion has resulted from clinical trials of fish oil in patients with CHD, which did not corroborate early observational findings, and newer results, which suggest clinical benefit due to a mechanism independent of lipid effects.
|
What Are Omega-3 Fatty Acids? |
|---|
|
TopIntroductionWhat Are Omega-3 Fatty...Fish Intake and Risk...Fish Intake and CHDConclusionsReferences |
|---|
Fish and other marine life are rich sources of a special class of polyunsaturated fatty acids known as the omega-3 or n-3 fatty acids.1 2 They are so named because the first of the several double bonds occur three carbon atoms away from the terminal end of the carbon chain. The three n-3 polyunsaturated fatty acids (n-3 PUFAs) are alpha linolenic acid (LNA), eicosapentenoic acid (EPA), and docosahexenoic acid (DHA). LNA is an 18–carbon chain fatty acid with three double bonds; in the form of tofu, soybean, and canola oil and nuts, it is an important plant-based source of n-3 PUFA for vegetarians and non–seafood eaters. EPA and DHA are very long–chain fatty acids obtained from marine sources. These, along with n-6 polyunsaturated fatty acids (n-6 PUFAs) that cannot be synthesized from nonlipid precursors such as linoleic acid, are considered essential fatty acids that must be consumed in the diet. The n-6 PUFAs are obtained primarily from plant sources, especially seeds. Arachidonic acid is a long-chain n-6 PUFA that is found in meats, fish, and plants or is synthesized from linoleic acid. Arachadonic acid and marine lipids both serve as key intermediates for eicosanoids like thromboxanes and prostacyclins, which are important for platelet and vessel wall physiology.
|
Fish Intake and Risk Factors |
|---|
|
TopIntroductionWhat Are Omega-3 Fatty...Fish Intake and Risk...Fish Intake and CHDConclusionsReferences |
|---|
Effects of Omega-3 Fatty Acids and Lipoproteins
The addition of omega-3 fatty acids to the diet lowers triglyceride levels, an effect that is pronounced in those with marked hypertriglyceridemia.3 The triglyceride-lowering effect is not seen with plant sources of n-3 PUFA.4 In those patients with type V hyperlipidemia, the use of fish oil supplements is an important therapeutic option.5 Connor6 listed the following putative mechanisms of dietary n-3 PUFA on lipoprotein metabolism in humans: (1) inhibition of VLDL triglyceride synthesis, (2) decreased apoprotein B synthesis, (3) enhancement of VLDL turnover with an increased fractional catabolic rate of VLDL, (4) depression of LDL synthesis, and (5) reduction of postprandial lipemia.
A critical review by Harris2 has clarified the discrepancy among fish oil studies reporting effects on LDL cholesterol (LDL-C). He noted that in the majority of studies reporting reductions in LDL-C levels, the saturated fat intake was lowered when subjects switched from the control diet to the fish oil diet. When fish oil is consumed and saturated fat intake is constant, LDL-C levels either do not change or may increase.
Although fish oil is not recommended in the treatment of hypercholesterolemia, it does have a role in the treatment of lipoprotein disorders characterized by severe hypertriglyceridemia. It can be quite useful in those severely hypertriglyceridemic (triglyceride >1000 mg/dL) patients for whom attempts to correct secondary causes (through diet, exercise, and gemfibrozil) have proved inadequate.7 Although a negative aspect is the concomitant elevation in LDL-C that occurs when fish oils are given to these patients with lower plasma levels of triglyceride, this is usually not a problem for those with severe hypertriglyceridemia, because LDL-C values are usually quite low. It can be a problem for those with more modest elevations of triglycerides in whom the elevation of LDL-C will actually move the patient away from the desired LDL-C goal.
Fish oil supplementation does not appear to impair glucose tolerance in nondiabetic coronary bypass patients.8 Among diabetics, initial studies showed deterioration of glucose tolerance with fish oil consumption.9 Nonetheless, Connor and coworkers10 designed a longer term study in which body weights were unchanged between fish oil and olive oil groups and no deterioration in glucose homeostasis was demonstrated in those individuals with diabetes. Westerveld and colleagues11 conducted a randomized, blinded, placebo-controlled trial that also documented reduced platelet aggregation as well as triglyceride lowering in the fish oil group. In both trials the fall in triglyceride level was accompanied by a rise in LDL-C similar to that seen in studies of patients with combined hyperlipidemia.12 This rise in LDL-C level was not seen when a low dose of omega-3 fatty acids was given to 20 ambulatory subjects with non–insulin-dependent diabetes mellitus in a randomized, double-blind, prospective, controlled clinical trial.13 Although sample size may have been inadequate to show an LDL-C effect, fish oil significantly inhibited platelet aggregation and thromboxane A2 production, while it reduced triglyceride levels by 44 mg/dL and decreased upright systolic blood pressure by 8 mm Hg compared with safflower oil. Finally, a recent study looking at vascular reactivity suggested that fish oil ingestion in diabetics could favorably alter arterial wall compliance without affecting fasting blood sugar, cholesterol, or blood pressure.14 Clearly, further research on the use of n-3 PUFA in diabetics is required.
Effect of Omega-3 Fatty Acids on Hypertension
A meta-analysis of placebo-controlled studies showed that fish oil reduced blood pressure in a dose-response fashion in those with hypertension and hypercholesterolemia but not in those participants with normal blood pressures.15 The effects were small, and it is not clear whether this effect is sustained over the long term.
Effect of Omega-3 Fatty Acids on Coagulation Profiles
A concise review of studies on the prevention of thrombosis in laboratory animals and in humans emphasized the important role of n-3 PUFA, which affects cellular responses in platelets, monocytes, and endothelial cells.16 The reduced platelet aggregation and prolonged bleeding times of the Greenland Eskimos suggested an important mechanism by which n-3 PUFAs could affect CHD.17 When bleeding times are measured, the effects of fish oil are additive to those of aspirin.18 Studies in swine fed high cholesterol diets with and without cod liver oil showed that there was less coronary atherosclerosis in the cod liver oil group but that there was no relationship to lipid changes. The pigs fed cod liver oil had significant decreases in serum thromboxane B2 levels and increases in platelet fatty acid deposition of EPA.19 Fish oil supplements increased levels of tissue plasminogen activator (TPA) and decreased concentrations of plasminogen activator inhibitor, both enhancers of fibrinolysis.20 One study comparing fish oil with rapeseed oil noted that fish oil decreased lipoprotein(a) by 14%.21 This effect was not seen in all male subjects who were hospitalized with CHD but did correlate with a large reduction in TPA. The Atherosclerosis Risk in Communities study compiled data from four US communities (15 000 participants, both black and white) on six hemostatic factors: fibrinogen, factor VII, factor VIII, von Willebrand factor, protein C, and antithrombin III.22 These were communities not known for their high intake of fish. Dietary intake of n-3 PUFA showed negative associations with levels of fibrinogen, factor VIII, and von Willebrand factor and a positive association with protein C (whites only). These findings may help explain, in part, the reduced incidence of vein graft occlusion seen in patients after coronary artery bypass grafting who receive n-3 PUFA.23 In a randomized controlled trial of dietary supplementation with n-3 fatty acids in bypass patients who received usual anticoagulation with aspirin or warfarin, an inverse relation between relative change in serum phospholipid n-3 fatty acids and vein graft occlusions was observed. Thus, the prevention of thrombosis remains a promising area for n-3 PUFA research.
Effect of Omega-3 Fatty Acids on Immune Response
The potent anti-inflammatory effects of fish oils and their effects on the immune response are beyond the scope of this review. Worthy of mention are the detailed studies of Meydani et al24 on immune responses seen with dietary fish supplementation. They showed decreased cell-mediated immunity when the Step II National Cholesterol Education Program (or AHA) diet was supplemented with a high fish intake as compared with one low in fish intake (121 to 188 g of fish per day versus 33 g of fish per day). The clinical significance of this important finding needs further investigation.
|
Fish Intake and CHD |
|---|
|
TopIntroductionWhat Are Omega-3 Fatty...Fish Intake and Risk...Fish Intake and CHDConclusionsReferences |
|---|
Observational Studies
Early studies of Greenland Eskimos (Inuit) highlighted their lower coronary mortality compared with their Danish counterparts. The Eskimos' diet included a strikingly higher intake of n-3 PUFAs rich in marine sources such as seal and whale that resulted in lower blood cholesterol, lower triglycerides, lower LDL-C, lower VLDL cholesterol, increased HDL cholesterol, increased bleeding times, and lower rates of CHD. In addition, prospective epidemiological studies from the Netherlands, Chicago, and the Multiple Risk Factor Intervention Trial confirmed that men who ate at least some fish per week had a lower mortality from CHD than those men who ate none.25 26 27 28 On the other hand, two studies describing populations with high intakes of fish did not show such a beneficial effect.29 30
Clinical Trials
There is no convincing role for fish oil supplements in the prevention of CHD. The strongest evidence indicating a beneficial effect of fish intake on CHD came from the Diet and Reinfarction Trial (DART), in which men who were instructed to eat fish after myocardial infarction (MI) had a 29% decline in all-cause mortality as compared with those in the placebo group.31 No significant lowering of cholesterol was seen, and very few men were taking aspirin. Yet the Health Professionals Follow-up Study,32 a large-scale prospective cohort study, reported no association between increasing fish intake and CHD. The authors concluded that increasing fish intake beyond one or two servings per week is not likely to improve the primary prevention of CHD.
A nested case-control study was conducted among the 14 916 participants in the Physicians' Health Study.33 Each participant with MI was matched by smoking status and age with a randomly chosen control participant who had not developed CHD. Fish oil intake was estimated by measuring plasma levels in cholesterol esters and phospholipids. No association was found between fish oil levels and the incidence of MI even when results were adjusted for major cardiovascular risk factors. Although early trials suggested that fish oil held some promise if ingested early before angioplasty, a clinical trial large enough to find a significant effect did not, despite a dose of 8 g/d of n-3 PUFA.34 This trial did document the safety of fish oil supplementation without any evidence of excess bleeding in the patients who all took aspirin. Moreover, a clinical trial with angiographic end points showed that among normocholesterolemic men with CHD, fish oil treatment (6 g n-3 PUFA for 2 years) did not produce significant changes in the diameter of the coronary arteries.35
Effects of Omega-3 Fatty Acids on Sudden Death
DART peaked interest in whether a diet rich in fish oil could reduce risk of sudden death because of the striking difference in sudden deaths seen early in the trial, suggesting a possible action on either thrombosis or arrhythmic death rather than on atherosclerosis.9 Support for the latter hypothesis came from the Lyon Trial,36 which compared a "Mediterranean-type" diet rich in LNA with the AHA Step I diet in patients with known MI. Although no improvement in lipids, lipoproteins, and body mass index was seen, there was a striking difference in mortality, with eight sudden deaths in the control group and none in the alpha LNA–rich diet group. The risk ratio of cardiac death was 0.19 (95% CI, 0.06 to 0.65), with P<.002. These findings were extended by the carefully done population-based case-control study from Seattle and King County, Washington.37 Among 334 patients with primary cardiac arrest, the intake of n-3 PUFA per month was significantly less than that seen in age- and sex-matched community controls. The data suggested that an intake of 5.5 g of n-3 PUFA per month (equivalent to one fatty fish meal per week) was associated with a 50% reduction in the risk of primary cardiac arrest after adjustment for potential confounding factors. Moreover, studies of red blood cell membrane n-3 PUFA in both patients and controls allowed calculation of risk based on this sensitive parameter of dietary n-3 PUFA intake. These findings were consistent with experimental evidence suggesting that the n-3 PUFAs have an important effect on vulnerability to ventricular fibrillation in the setting of myocardial ischemia.38 Of additional interest are recent data showing suppression of premature ventricular contractions (PVCs) in middle-aged patients with frequent PVCs randomly assigned to take either fish oil (as cod liver oil containing 2.4 g of n-3 PUFA) or sunflower seed oil.39 Clearly, further studies are needed to explore the potential of fish oil in the prevention of sudden cardiac death.
|
Conclusions |
|---|
|
TopIntroductionWhat Are Omega-3 Fatty...Fish Intake and Risk...Fish Intake and CHDConclusionsReferences |
|---|
When considering cardiovascular health, it seems premature to recommend general usage until compelling evidence for the beneficial action of fish oil supplements is at hand. Although doses of 3 to 8 g of n-3 PUFA per day in those with CHD were not associated with significant adverse effects in recent clinical trials,8 34 evidence for beneficial effects in CHD patients is either lacking or needs additional study. Currently, fish oil capsules can only be recommended for the infrequent patients with severe, treatment-resistant hypertriglyceridemia who are at increased risk for pancreatitis. Potential side effects should be kept in mind (Table
1 40 ). On the other hand, inclusion of marine sources of the n-3 PUFA in the diet seems reasonable because they are good sources of protein without the accompanying high saturated fat seen in fatty meat products. Moreover, as Harris has noted, the potential for benefit remains high, since dietary fish oils affect "a myriad of potentially atherogenic processes."41 This requires the continued support of cardiovascular research on the n-3 PUFA.
|
|
Footnotes |
|---|
Single reprints are free: Call 1-800-242-8721 (US only) or write American Heart Association, Public Information, 7272 Greenville, Dallas, TX 75231-4596.
"Fish Consumption, Fish Oil, Lipids, and Coronary Heart Disease" was approved by the Science Advisory and Coordinating Committee of the American Heart Association in July 1996.
Single reprints are free: Call 1-800-242-8721 (US only) or write American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596.
|
References |
|---|
|
TopIntroductionWhat Are Omega-3 Fatty...Fish Intake and Risk...Fish Intake and CHDConclusionsReferences |
|---|
1. Nettleton JA. Omega-3 Fatty Acids and Health. New York, NY: Chapman & Hall; 1995:354.
2. Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res.. 1989;30:785-807.[Abstract]
3. Pownall HJ, Raynaud AS, Harper E, Choi S, Rohrback K, Pao Q, Reeves RS, Gotto AM. Effect of 12 weeks of dietary fish oil, polyunsaturated fat, monounsaturated fat in the human plasma lipoprotein structure and composition. Proceedings of the Scientific Conference on Omega-3 Fatty Acids in Nutrition, Vascular Biology, and Medicine, Houston, Tex, April 17-19, 1994:64-78.
4.
Kestin M, Clifton P, Belling GB, Nestel PJ. n-3 Fatty acids of marine origin lower systolic blood pressure and triglycerides but raise LDL cholesterol compared with n-3 and n-6 fatty acids from plants. Am J Clin Nutr.. 1990;51:1028-1034.
5. Phillipson BE, Rothrock DW, Connor WE, Harris WS, Illingworth DR. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med.. 1985;312:1210-1216.[Abstract]
6. Connor WE. The impact of dietary omega-3 fatty acids on the synthesis and clearance of apo b lipoproteins and chylomicrons. Proceedings of the Scientific Conference on Omega-3 Fatty Acids in Nutrition, Vascular Biology, and Medicine, Houston, Tex, April 17-19, 1994:19-32.
7. Connor WE, DeFrancesco CA, Connor SL. N-3 fatty acids from fish oil: effects on plasma lipoproteins and hypertriglyceridemic patients. Ann N Y Acad Sci.. 1993;683:16-34.[Medline] [Order article via Infotrieve]
8.
Eritsland J, Arnesen H, Seljeflot I, Hostmark AT. Long-term metabolic effects of n-3 polyunsaturated fatty acids in patients with coronary artery disease. Am J Clin Nutr.. 1995;61:831-836.
9. Kasim SE. Dietary marine fish oils and insulin action in type 2 diabetes. Ann N Y Acad Sci.. 1993;683:250-257.[Medline] [Order article via Infotrieve]
10. Connor WE, Prince MJ, Ullmann D, Riddle M, Hatcher L, Smith FE, Wilson D. The hypotriglyceridemic effect of fish oil in adult-onset diabetes without adverse glucose control. Ann N Y Acad Sci.. 1993;683:337-440.[Medline] [Order article via Infotrieve]
11. Westerveld HT, de Graaf JC, van Breugel HH, Akkerman JW, Sixma JJ, Erkelens DW, Banga JD. Effects of low-dose EPA-E on glycemic control, lipid profile, lipoprotein(a), platelet aggregation, viscosity, and platelet and vessel wall interaction in NIDDM. Diabetes Care.. 1993;16:683-688.[Abstract]
12.
Zambon S, Friday KE, Childs MT, Fujimoto WY, Bierman EL, Ensinck JW. Effect of glyburide and omega 3 fatty acid dietary supplements on glucose and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Am J Clin Nutr.. 1992;56:447-454.
13. Axelrod L, Camuso J, Williams E, Kleinman K, Briones E, Schoenfeld D. Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM: a randomized, prospective, double-blind, controlled study. Diabetes Care.. 1994;17:37-44.[Abstract]
14.
McVeigh GE, Brennan GM, Cohn JN, Finkelstein SM, Hayes RJ, Johnston GD. Fish oil improves arterial compliance in non–insulin-dependent diabetes mellitus. Arterioscler Thromb.. 1994;14:1425-1429.
15.
Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation.. 1993;88:523-533.
16. Nordoy A. Omega 3-Fatty Acids and Thrombosis. Proceedings of the Scientific Conference on Omega-3 Fatty Acids in Nutrition, Vascular Biology, and Medicine, Houston, Tex, April 17-19, 1994:221-231.
17. Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet.. 1978;2:117-119.[Medline] [Order article via Infotrieve]
18. Thorngren M, Gustafson A. Effects of 11-week increases in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggregation. Lancet.. 1981;2:1190-1193.[Medline] [Order article via Infotrieve]
19. Weiner BH, Ockene IS, Levine PH, Cuenoud HF, Fisher M, Johnson BF, Daoud AS, Jarmolych J, Hosmer D, Johnson MH, et al. Inhibition of atherosclerosis by cod-liver oil in a hyperlipidemic swine model. N Engl J Med.. 1986;315:841-846.[Abstract]
20. Barcelli U, Glas-Greenwalt P, Pollak VE. Enhancing effect of dietary supplementation with omega-3 fatty acids on plasma fibrinolysis in normal subjects. Thromb Res.. 1985;39:307-312.[Medline] [Order article via Infotrieve]
21. Hermann W, Biermann J, Kostner GM. Comparison of effects of N-3 to N-6 fatty acids on serum levels of lipoprotein(a) in patients with coronary artery disease. Am J Cardiol.. 1995;76:459-462.[Medline] [Order article via Infotrieve]
22.
Shahar E, Folsom AR, Wu KK, Dennis BH, Shimakawa T, Conlan MG, Davis CE, Williams OD. Associations of fish intake and dietary n-3 polyunsaturated fatty acids with a hypocoagulable profile: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb.. 1993;13:1205-1212.
23. Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol.. 1996;77:31-36.[Medline] [Order article via Infotrieve]
24. Meydani SN, Lichtenstein AH, Cornwall S, Meydani M, Goldin BR, Rasmussen H, Dinarello CA, Schaefer EJ. Immunologic effects of a National Cholesterol Education Panel step-2 diet with and without fish-derived N-3 fatty acid enrichment. J Clin Invest.. 1993;92:105-113.
25. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med.. 1985;312:1205-1209.[Abstract]
26. Shekelle RB, Missell L, Paul O, Shryock AM, Stamler J. Fish consumption and mortality from coronary heart disease. N Engl J Med.. 1985;313:820.[Medline] [Order article via Infotrieve]
27. Dolecek TA, Grandits G. Dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial (MRFIT). World Rev Nutr Diet.. 1991;66:205-216.[Medline] [Order article via Infotrieve]
28.
Kromhout D, Feskens EJM, Bowles CH. The protective effect of a small amount of fish on coronary heart disesae mortality in an elderly population. Int J Epidemiol.. 1995;24:340-345.
29. Vollset SE, Heuch I, Bjelke E. Fish consumption and mortality from coronary heart disease. N Engl J Med.. 1985;313:820-821. Letter.
30. Curb JD, Reed DM. Fish consumption and mortality from coronary heart disease. N Engl J Med.. 1985;313:821-822. Letter.
31. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet.. 1989;2:757-761.[Medline] [Order article via Infotrieve]
32.
Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med.. 1995;332:977-982.
33. Guallar E, Hennekens CH, Sacks FM, Willett WC, Stampfer MJ. A prospective study of plasma fish oil levels and incidence of myocardial infarction in U.S. male physicians. J Am Coll Cardiol.. 1995;25:387-394.[Abstract]
34.
Leaf A, Jorgensen MB, Jacobs AK, Cote G, Schoenfeld DA, Scheer J, Weiner BH, Slack JD, Kellett MA, Raizner AE, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation.. 1994;90:2248-2257.
35. Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC. Controlled trial of fish oil for regression of human coronary atherosclerosis: HARP Research Group. J Am Coll Cardiol.. 1995;25:1492-1498.[Abstract]
36. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet.. 1994;343:1454-1459.[Medline] [Order article via Infotrieve]
37.
Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, Bovbjerg V, Arbogast P, Smith H, Kushi LH, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA.. 1995;274:1363-1367.
38.
Billman GE, Hallaq H, Leaf A. Prevention of ischemia-induced ventricular fibrillation by omega 3 fatty acids. Proc Natl Acad Sci U S A.. 1994;91:4427-4430.
39. Sellmayer A, Witzgall H, Lorenz RL, Weber PC. Effects of dietary fish oil on ventricular premature complexes. Am J Cardiol.. 1995;76:974-977.[Medline] [Order article via Infotrieve]
40. Mueller SD, D'Aunno D, Willerson JT. Fish oils: what to tell our patients? Contemporary Internal Medicine.. 1992;2:87-89.
41. Harris WS. Dietary fish oil and blood lipids. Curr Opin Lipidol.. 1996;7:3-7.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  A. Yates, J. Norwig, J. C. Maroon, J. Bost, J. P. Bradley, M. Duca, D. A. Wecht, R. Grove, A. Iso, I. Cobb, et al. Evaluation of Lipid Profiles and the Use of Omega-3 Essential Fatty Acid in Professional Football Players Sports Health: A Multidisciplinary Approach, January 1, 2009; 1(1): 21 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Diaz Encarnacion, G. M. Warner, C. E. Gray, J. Cheng, H. K. H. Keryakos, K. A. Nath, and J. P. Grande Signaling pathways modulated by fish oil in salt-sensitive hypertension Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1323 - F1335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Oe, T Hozumi, E Murata, H Matsuura, K Negishi, Y Matsumura, S Iwata, K Ogawa, K Sugioka, Y Takemoto, et al. Arachidonic acid and docosahexaenoic acid supplementation increases coronary flow velocity reserve in Japanese elderly individuals Heart, March 1, 2008; 94(3): 316 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Zaloga, K. A. Harvey, W. Stillwell, and R. Siddiqui Trans Fatty Acids and Coronary Heart Disease Nutr Clin Pract, October 1, 2006; 21(5): 505 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. A Castro, L. P Barroso, and P. Sinnecker Functional foods for coronary heart disease risk reduction: a meta-analysis using a multivariate approach Am. J. Clinical Nutrition, July 1, 2005; 82(1): 32 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Surette, M. Edens, F. H. Chilton, and K. M. Tramposch Dietary Echium Oil Increases Plasma and Neutrophil Long-Chain (n-3) Fatty Acids and Lowers Serum Triacylglycerols in Hypertriglyceridemic Humans J. Nutr., June 1, 2004; 134(6): 1406 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Kris-Etherton, W. S. Harris, L. J. Appel, and for the AHA Nutrition Committee Omega-3 Fatty Acids and Cardiovascular Disease: New Recommendations From the American Heart Association Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 151 - 152. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Kris-Etherton, W. S. Harris, L. J. Appel, and for the Nutrition Committee Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): e20 - 30. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Kris-Etherton, W. S. Harris, L. J. Appel, and for the Nutrition Committee Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease Circulation, November 19, 2002; 106(21): 2747 - 2757. [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Lorgeril, P. Salen, P. Defaye, P. Mabo, and F. Paillard Dietary prevention of sudden cardiac death Eur. Heart J., February 2, 2002; 23(4): 277 - 285. [Full Text] [PDF]
|
|
|
|
 |
|
 D.S. Siscovick, T.E. Raghunathan, R. Lemaitre, I. King, and L.A. Cobb Long-chain n-3 polyunsaturated fatty acids and out-of-hospital primary cardiac arrest: clinical and public health implications of observational studies and clinical trials Eur. Heart J. Suppl., June 1, 2001; 3(suppl_D): D70 - D74. [Abstract] [PDF]
|
|
|
|
 |
|
 M. B. Engler and M. M. Engler Docosahexaenoic Acid-Induced Vasorelaxation in Hypertensive Rats: Mechanisms of Action Biol Res Nurs, October 1, 2000; 2(2): 85 - 95. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Oberman Hypertriglyceridemia and Coronary Heart Disease J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2098 - 2105. [Full Text]
|
|
|
|
|
|
D. S Siscovick, T. Raghunathan, I. King, S. Weinmann, V. E Bovbjerg, L. Kushi, L. A Cobb, M. K Copass, B. M Psaty, R. Lemaitre, et al. Dietary intake of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest Am. J. Clinical Nutrition, January 1, 2000; 71(1): 208S - 212S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Kris-Etherton, S. Yu-Poth, J. Sabate, H. E Ratcliffe, G. Zhao, and T. D Etherton Nuts and their bioactive constituents: effects on serum lipids and other factors that affect disease risk Am. J. Clinical Nutrition, September 1, 1999; 70(3): 504S - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Guallar, A. Aro, F. J. Jimenez, J. M. Martin-Moreno, I. Salminen, P. van't Veer, A. F. M. Kardinaal, J. Gomez-Aracena, B. C. Martin, L. Kohlmeier, et al. Omega-3 Fatty Acids in Adipose Tissue and Risk of Myocardial Infarction : The EURAMIC Study Arterioscler Thromb Vasc Biol, April 1, 1999; 19(4): 1111 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Lorgeril Dietary arginine and the prevention of cardiovascular diseases Cardiovasc Res, March 1, 1998; 37(3): 560 - 563. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||